Regional Kidney Paired Donor Exchange in Sensitized Patients
NCT ID: NCT01896089
Last Updated: 2016-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tolerant Kidney Transplant Recipients
NCT01338779
Immune Response in Desensitized Patients
NCT05785936
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
NCT05879302
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
NCT06878560
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
NCT00001858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Must be at least 18 years old
3. Meet all recipient selection criteria of the transplant center
4. Listed on the deceased donor kidney waiting list for renal transplant at a participating center
5. Potential recipients must:
Group 1: have one or more medically suitable donors who are ABO incompatible or HLA incompatible (defined as positive serologic cross-match); or
Group 2: have a medically suitable donor that is otherwise deemed incompatible due to age, size, or other mismatch by their respective transplant center; or
Group 3: be listed on the deceased donor waiting list for ≥ one year without an identifiable living donor and have a PRA% ≥ 60%
1. Must provide informed consent in accordance with the process outlined in the Informed Consent Requirements Section of the KPD Program Manual of Operations
2. Must be at least 18 years old
3. Meet all living donor selection criteria of the transplant center
4. Meet the evaluation requirements set forth in the Living Donor Evaluation Section of the KPD Program Operational Guidelines
Exclusion Criteria
1. Do not meet selection criteria of the transplant center
2. Eligible compatible donor at the time of enrollment
3. Inactive (not eligible to receive a kidney) on the deceased donor waitlist
4. Pregnant or breast feeding
D. Donors
1. Unwilling or unable to provide informed consent
2. Have identified barriers to donation as set forth in the Living Donor Evaluation Section of the KPD Program Manual of Operations (Appendix A)
3. Must not be currently listed as a potential living donor for any other recipient registered in the KPD system
4. Pregnant or breast feeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BiologicTx, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa Florence, MD
Role: PRINCIPAL_INVESTIGATOR
Swedish Medical Center
Andrew Weiss, MD
Role: PRINCIPAL_INVESTIGATOR
Virginia Mason Medical Center
Douglas Norman, MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Richard Carson, MD
Role: PRINCIPAL_INVESTIGATOR
Sacred Heart Medical Center (Spokane)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Mason Medical Center
Seattle, Washington, United States
Swedish Medical Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KPD6172013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.